Seelaus Asset Management’s Arcus Biosciences RCUS Stock Holding History

Seelaus Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	+6,540	New	+$162K	0.14%	194
2025 Q4	–	Sell	-13,000	Closed	-$177K	–	185
2025 Q3	$177K	Hold	13,000	–	–	0.14%	168
2025 Q2	$106K	Hold	13,000	–	–	0.09%	170
2025 Q1	$102K	Hold	13,000	–	–	0.1%	165
2024 Q4	$194K	Hold	13,000	–	–	0.18%	153
2024 Q3	$199K	Hold	13,000	–	–	0.18%	153
2024 Q2	$198K	Buy	+13,000	New	+$210K	0.2%	151

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Seelaus Asset Management's RCUS Position: Q2 2026 in Review

Seelaus Asset Management opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 6,540 shares worth $202K. The stake represents 0.14% of the portfolio and ranks #194 among its holdings. This is a return to the name: Seelaus Asset Management previously reported a position in RCUS as recently as Q3 2025.

Seelaus Asset Management first reported a position in RCUS in Q2 2024 and has held it in 7 quarters since. 72 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Seelaus Asset Management held 6,540 shares of Arcus Biosciences worth $202K as of Q2 2026.
Arcus Biosciences was a new Seelaus Asset Management position in Q2 2026.
Arcus Biosciences made up 0.14% of Seelaus Asset Management's portfolio in Q2 2026, its #194 holding.
Seelaus Asset Management first reported a position in Arcus Biosciences in Q2 2024 and has held it in 7 quarters since.
72 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Seelaus Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.